Incidence of Hyper Progressive Disease in Combination Immunotherapy and Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Monotherapy for Unresectable Hepatocellular Carcinoma

Overview

Journal Liver Cancer

Date 2024 Feb 12

PMID 38344443

Authors

Tomoko Aoki

Masatoshi Kudo

Kazuomi Ueshima

Masahiro Morita

Hirokazu Chishina

Masahiro Takita

Satoru Hagiwara

Hiroshi Ida

Yasunori Minami

Masakatsu Tsurusaki

Naoshi Nishida

Affiliations

Soon will be listed here.

Abstract

Introduction: Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) signaling blockade is the most effective strategy for the treatment of immune evading hepatocellular carcinoma (HCC). While immune checkpoint inhibitor has revolutionized the concept of cancer treatment, it has also led to unexpected tumor growth. Regulatory T cells express PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) receptors, which are proliferated and activated by antibody binding, and their ratio to CD8+ T cells is altered, which is one of the causes for hyper progressive disease (HPD). We examined the frequency of HPD in anti-PD-1/PD-L1 monotherapy and combination therapy with vascular endothelial growth factor (VEGF) antibody and anti-CTLA-4 antibodies.

Methods: This was a prospective and retrospective cohort study which enrolled 198 patients with unresectable HCC from January 2015 to December 2021 at the Kindai University Hospital. Fifty-eight patients received anti-PD-1/PD-L1 monotherapy, 119 patients combination with VEGF antibody, and 21 patients combination with anti-CTLA-4 antibody. We defined HPD as tumor growth rate (TGR) ratio ≥4, ΔTGR ≥40%, and tumor growth kinetics ratio ≥4.

Results: The HPD rate was 10.3% (6/58) in anti-PD-1/PD-L1 monotherapy, 1.7% (2/119) in combination with VEGF antibody, and 4.8% (1/21) in combination with anti-CTLA-4 antibody ( = 0.034). The odds ratio for HPD in the combined anti-CTLA-4 antibody group was 0.433 (95% confidence interval [CI]: 0.05-3.83) when compared to the anti-PD-1/PD-L1 monotherapy group and 2.93 (95% CI: 0.25-33.79) when compared to the combined VEGF antibody group.

Conclusion: The frequency of HPD in unresectable HCC compared to anti-PD-1/PD-L1 monotherapy was decreased with the combination with anti-VEGF antibody and not increased with anti-CTLA-4 antibody. Anti-PD-1/PD-L1 combined with anti-CTLA-4 antibody is now available in real-world and needs to be further validated with accumulated clinical practice.

Citing Articles

Prognostic analysis of systemic antitumor therapy in young patients with advanced liver cancer: A cohort study.

Zhang J, Chen C, Xia Z, Xiong X, Liu P, Xu Y Oncol Lett. 2024; 28(3):410.

PMID: 38988447 PMC: 11234805. DOI: 10.3892/ol.2024.14544.

Effect of 23‑hydroxybetulinic acid on lung adenocarcinoma and its mechanism of action.

Tan B, Lan X, Zhang Y, Liu P, Jin Q, Wang Z Exp Ther Med. 2024; 27(6):239.

PMID: 38633355 PMC: 11019653. DOI: 10.3892/etm.2024.12527.

References

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y . The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol. 2020; 21(11):1346-1358. DOI: 10.1038/s41590-020-0769-3. View

Bulliard Y, Jolicoeur R, Windman M, Rue S, Ettenberg S, Knee D . Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med. 2013; 210(9):1685-93. PMC: 3754864. DOI: 10.1084/jem.20130573. View

Suzuki H, Onishi H, Morisaki T, Tanaka M, Katano M . Intratumoral FOXP3+VEGFR2+ regulatory T cells are predictive markers for recurrence and survival in patients with colorectal cancer. Clin Immunol. 2012; 146(1):26-33. DOI: 10.1016/j.clim.2012.10.007. View

Maesaka K, Sakamori R, Yamada R, Tahata Y, Imai Y, Ohkawa K . Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy. Hepatol Res. 2021; 52(3):298-307. DOI: 10.1111/hepr.13741. View

Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S . Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res. 2016; 23(8):1920-1928. DOI: 10.1158/1078-0432.CCR-16-1741. View

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

Leach D, Krummel M, Allison J . Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996; 271(5256):1734-6. DOI: 10.1126/science.271.5256.1734. View

Hodi F, Butler M, Oble D, Seiden M, Haluska F, Kruse A . Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008; 105(8):3005-10. PMC: 2268575. DOI: 10.1073/pnas.0712237105. View

10.

Aoki T, Nishida N, Kudo M . Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity. J Histochem Cytochem. 2021; 70(1):53-81. PMC: 8721576. DOI: 10.1369/00221554211056853. View

11.

Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

12.

Champiat S, Ferrara R, Massard C, Besse B, Marabelle A, Soria J . Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol. 2018; 15(12):748-762. DOI: 10.1038/s41571-018-0111-2. View

13.

Orbach A, Rachmilewitz J, Parnas M, Huang J, Tykocinski M, Dranitzki-Elhalel M . CTLA-4 . FasL induces early apoptosis of activated T cells by interfering with anti-apoptotic signals. J Immunol. 2007; 179(11):7287-94. DOI: 10.4049/jimmunol.179.11.7287. View

14.

Suzuki H, Onishi H, Wada J, Yamasaki A, Tanaka H, Nakano K . VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. Eur J Immunol. 2009; 40(1):197-203. DOI: 10.1002/eji.200939887. View

15.

Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G . Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clin Cancer Res. 2018; 25(3):989-999. DOI: 10.1158/1078-0432.CCR-18-1390. View

16.

Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O . VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 2012; 73(2):539-49. DOI: 10.1158/0008-5472.CAN-12-2325. View

17.

Kudo M . Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma. Liver Cancer. 2020; 9(5):479-490. PMC: 7548850. DOI: 10.1159/000509554. View

18.

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

19.

Marrero J, Kulik L, Sirlin C, Zhu A, Finn R, Abecassis M . Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68(2):723-750. DOI: 10.1002/hep.29913. View

20.

Selby M, Engelhardt J, Quigley M, Henning K, Chen T, Srinivasan M . Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2014; 1(1):32-42. DOI: 10.1158/2326-6066.CIR-13-0013. View